NFA
CRBP icon

Nationwide Fund Advisors’s Corbus Pharmaceuticals CRBP Stock Holding History

Nationwide Fund Advisors’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-834
Closed -$179K – 470
2017
Q3 		$179K Hold
834
– – ﹤0.01% 2682
2017
Q2 		$158K Buy
+834
New +$164K ﹤0.01% 2729

Other funds holding CRBP

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nationwide Fund Advisors's CRBP Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Corbus Pharmaceuticals (CRBP) in Q4 2017, closing a stake of 834 shares — an estimated $179K sold.

Nationwide Fund Advisors first reported a position in CRBP in Q2 2017 and held it in 2 quarters. The position peaked at $179K in Q3 2017. 88 funds tracked by Wall St. Rank hold CRBP as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Corbus Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 834 Corbus Pharmaceuticals shares in Q4 2017, an estimated $179K.
  • Nationwide Fund Advisors first reported a position in Corbus Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Nationwide Fund Advisors's Corbus Pharmaceuticals position peaked at $179K in Q3 2017.
  • 88 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.